Show simple item record

dc.contributor.authorRatti, M
dc.contributor.authorLampis, A
dc.contributor.authorHahne, JC
dc.contributor.authorPassalacqua, R
dc.contributor.authorValeri, N
dc.date.accessioned2018-09-04T13:53:02Z
dc.date.issued2018-11
dc.identifier.citationCellular and molecular life sciences : CMLS, 2018, 75 (22), pp. 4151 - 4162
dc.identifier.issn1420-682X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2559
dc.identifier.eissn1420-9071
dc.identifier.doi10.1007/s00018-018-2906-9
dc.description.abstractGastric cancer is one of the most aggressive malignancies, with limited treatment options in both locally advanced and metastatic setting, resulting in poor prognosis. Based on genomic characterization, stomach tumour has recently been described as a heterogeneous disease composed by different subtypes, each of them with peculiar molecular aspects and specific clinical behaviour. With an incidence of 22% among all western gastric tumour cases, stomach cancer with microsatellite instability was identified as one of these subgroups. Retrospective studies and limited prospective trials reported differences between gastric cancers with microsatellite stability and those with instability, mainly concerning clinical and pathological features, but also in regard to immunological microenvironment, correlation with prognostic value, and responses to treatment. In particular, gastric cancer with microsatellite instability constitutes a small but relevant subgroup associated with older age, female sex, distal stomach location, and lower number of lymph-node metastases. Emerging data attribute to microsatellite instability status a favourable prognostic meaning, whereas the poor outcomes reported after perioperative chemotherapy administration suggest a detrimental role of cytotoxic drugs in this gastric cancer subgroup. The strong immunogenicity and the widespread expression of immune-checkpoint ligands make microsatellite instability subtype more vulnerable to immunotherapeutic approach, e.g., with anti-PD-L1 and anti-CTLA4 antibodies. Since gastric cancer with microsatellite instability shows specific features and clinical behaviour not overlapping with microsatellite stable disease, microsatellite instability test might be suitable for inclusion in a diagnostic setting for all tumour stages to guarantee the most targeted and effective treatment to every patient.
dc.formatPrint-Electronic
dc.format.extent4151 - 4162
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectStomach Neoplasms
dc.subjectAntineoplastic Agents
dc.subjectAntibodies, Monoclonal
dc.subjectDNA Repair
dc.subjectMicrosatellite Repeats
dc.subjectMicrosatellite Instability
dc.subjectTumor Microenvironment
dc.titleMicrosatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches.
dc.typeJournal Article
dcterms.dateAccepted2018-08-14
rioxxterms.versionofrecord10.1007/s00018-018-2906-9
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-11
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCellular and molecular life sciences : CMLS
pubs.issue22
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Evolutionary Genomics & Modelling
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Evolutionary Genomics & Modelling
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics
pubs.publication-statusPublished
pubs.volume75
pubs.embargo.termsNot known
icr.researchteamEvolutionary Genomics & Modellingen_US
icr.researchteamGastrointestinal Cancer Biology and Genomicsen_US
dc.contributor.icrauthorHahne, Jensen
dc.contributor.icrauthorLampis, Andreaen
dc.contributor.icrauthorValeri, Nicolaen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0